Processing

Please wait...

Settings

Settings

1. WO2000040227 - METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX

Publication Number WO/2000/040227
Publication Date 13.07.2000
International Application No. PCT/US2000/000179
International Filing Date 05.01.2000
Chapter 2 Demand Filed 04.08.2000
IPC
A61K 31/401 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
401Proline; Derivatives thereof, e.g. captopril
A61K 31/4178 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 38/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
14Peptides containing saccharide radicals; Derivatives thereof
A61K 38/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55Protease inhibitors
CPC
A61K 31/401
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
401Proline; Derivatives thereof, e.g. captopril
A61K 31/4178
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/573
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573substituted in position 21, e.g. cortisone, dexamethasone, prednisone ; or aldosterone
A61K 38/49
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
49Urokinase; Tissue plasminogen activator
A61K 38/556
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55Protease inhibitors
556Angiotensin converting enzyme inhibitors
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • UNIVERSITY OF UTAH [US/US]; 615 Arapeen Drive, Suite 110 Salt Lake City, UT 84108, US (AllExceptUS)
  • AMERICAN NATIONAL RED CROSS [US/US]; 15601 Crabbs Branch Way Rockville, MD 20855, US (AllExceptUS)
  • NOBLE, Nancy, A. [US/US]; US (UsOnly)
  • BORDER, Wayne, A. [US/US]; US (UsOnly)
  • LAWRENCE, Daniel, A. [US/US]; US (UsOnly)
Inventors
  • NOBLE, Nancy, A.; US
  • BORDER, Wayne, A.; US
  • LAWRENCE, Daniel, A.; US
Agents
  • MANDEL, Sara Lynn; Mandel & Adriano 35 No. Arroyo Parkway, Suite 60 Pasadena, CA 91103, US
Priority Data
60/114,79505.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX
(FR) PROCEDES DE TRAITEMENT D'ETATS ASSOCIES A L'ACCUMULATION D'UN EXCEDENT DE MATRICE EXTRACELLULAIRE
Abstract
(EN)
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGF$g(b), or using agents that inhibit TGF$g(b) in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a suject.
(FR)
La présente invention concerne divers procédés et diverses compositions pour réduire et empêcher un excédent de matrice extracellulaire dans un tissu et/ou un organe ou à l'emplacement d'une plaie. On utilise une combinaison d'agents inhibiteurs du TGF-bêta ou des agents inhibiteurs du TGF-bêta combinés avec des agents qui réduisent l'excédent de matrice extracellulaire. Les combinaisons et les procédés présentés sont utilisés pour le traitement des états tels que les fibroses et la cicatrisation qui résultent d'un excédent de matrice extracellulaire, altérant le tissu ou le fonctionnement d'un organe, ou encore l'aspect extérieur de la peau d'un sujet.
Other related publications
Latest bibliographic data on file with the International Bureau